Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Nymox Pharmaceutical's Enterprise Value is $11.30 Mil.
Nymox Pharmaceutical's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was $-1.42 Mil. Therefore, Nymox Pharmaceutical's EV-to-EBIT ratio for today is -7.94.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Nymox Pharmaceutical's Enterprise Value is $11.30 Mil.
Nymox Pharmaceutical's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was $-1.42 Mil. Therefore, Nymox Pharmaceutical's EV-to-EBITDA ratio for today is -7.94.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Nymox Pharmaceutical (OTCPK:NYMXF) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Nymox Pharmaceutical's current Enterprise Value is $11.30 Mil.
Nymox Pharmaceutical's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.42 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Nymox Pharmaceutical's current Enterprise Value is $11.30 Mil.
Nymox Pharmaceutical's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.42 Mil.
Nymox Pharmaceutical's current Enterprise Value is $11.30 Mil.
Nymox Pharmaceutical's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
Nymox Pharmaceutical's current Enterprise Value is $11.30 Mil.
Nymox Pharmaceutical's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.72 Mil.
Nymox Pharmaceutical's current Enterprise Value is $11.30 Mil.
Nymox Pharmaceutical's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.72 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nymox Pharmaceutical Enterprise Value Related Terms
Nymox Pharmaceutical Enterprise Value Historical Data
* Premium members only.
The historical data trend for Nymox Pharmaceutical's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NYMXF vs LYRA, RNAZ, TOVX: Enterprise Value Comparison
For the Biotechnology subindustry, Nymox Pharmaceutical's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nymox Pharmaceutical Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nymox Pharmaceutical's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Nymox Pharmaceutical's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Nymox Pharmaceutical's Enterprise Value for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nymox Pharmaceutical (NYMXF) has a Enterprise Value of $11.30 Mil as of Jul. 03, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Nymox Pharmaceutical and its competitors.
Is Nymox Pharmaceutical's Enterprise Value too high?
Nymox Pharmaceutical's current Enterprise Value is $11.30 Mil.
How does Nymox Pharmaceutical's Enterprise Value compare to LYRA and RNAZ?
Nymox Pharmaceutical's Enterprise Value of $11.30 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Nymox Pharmaceutical and its competitors. Nymox Pharmaceutical's current Enterprise Value is $11.30 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nymox Pharmaceutical stock overvalued right now?
Nymox Pharmaceutical (NYMXF) has a current Enterprise Value of $11.30 Mil. The current Enterprise Value is $11.30 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Nymox Pharmaceutical (NYMXF), the current Enterprise Value is $11.30 Mil as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nymox Pharmaceutical Corp is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of BPH and low-grade localized prostate cancer. The company also has an extensive patent portfolio covering its investigational drug as well as other therapeutic and diagnostic indications. It also has U.S. and patent rights for the use of statin drugs for the treatment and prevention of Alzheimer's disease. The company operates in one reportable segment, focused on researching and developing products for the aging population.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NYMXF has been successfully added to your 